Takeda Pharmaceutical Company
Tracked across 17 events · 248 articles · First seen Feb 19, 2026 · Last active Aug 19, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Tech
Impact: Takeda Pharmaceutical Company presented positive additional results from two pivotal studies for its drug oveporexton, which could redefine the standard of care for narcolepsy type 1, potentially increasing its market share and revenue in the pharmaceutical industry. Its shares were down 2.18% on the day of the announcement, but the long-term outlook is positive if the drug is approved.
Jun 15, 2026 · 6 articles
Business
Impact: Takeda Pharmaceutical Company is partnering with Insilico Medicine to integrate AI into its drug discovery process, aiming to accelerate the identification of novel drug candidates and transition to an AI-native discovery model. This collaboration grants Takeda exclusive worldwide rights to develop and commercialize therapeutics from this partnership.
Jul 02, 2026 · 8 articles
Regulatory
Impact: Takeda is the developer and manufacturer of QDENGA, the first dengue vaccine approved in India. This approval expands its market to India, the country with the highest dengue burden, and strengthens its global vaccine portfolio.
Jul 20, 2026 · 93 articles
Regulatory
The U.S. United States — Food and Drug Administration (FDA) approved Takeda Pharmaceutical Company's Orzeyful (oveporexton) as the first oral orexin receptor 2 agonist for the treatment of narcolepsy type 1 (NT1) in adults. This…
Impact: Takeda developed and received FDA approval for Orzeyful, its first-in-class orexin agonist for narcolepsy type 1. This approval strengthens its pipeline and market position, though the company expects no significant impact on its fiscal 2027 forecast.
Aug 05, 2026 · 21 articles
Business
Impact: Takeda Pharmaceutical Company terminated its collaboration agreement with Denali Therapeutics for DNL593 due to strategic considerations, not related to efficacy or safety data.
Apr 03, 2026 · 7 articles
Tech
Impact: Takeda Pharmaceutical Company is co-developing IBI363 with Innovent Biologics and will exclusively commercialize it globally outside the U.S. and greater China. The positive clinical results for IBI363 strengthen Takeda's oncology portfolio and future revenue potential.
May 21, 2026 · 9 articles
Tech
Cumulus Neuroscience announced the publication of final results from its CNS-102 study in Scientific Reports, demonstrating that its at-home NeuLogiq Platform is feasible, well tolerated, and highly usable for multimodal cognitive assessment in people living…
Impact: Takeda is a consortium member. The study's findings could influence its trial designs for neurodegenerative diseases.
Aug 18, 2026 · 6 articles
Business
Impact: Takeda Pharmaceutical's stock declined, showing a negative performance.
May 21, 2026 · 40 articles
Regulatory
Impact: Takeda is the Japanese laboratory that produces another dengue vaccine, which continues to be used without problems in Brazil, potentially seeing increased demand due to the suspension of the local vaccine.
Jun 08, 2026 · 7 articles
Business
Impact: Takeda Pharmaceutical Company is the licensee for rusfertide, another peptide discovered by AnBogen Therapeutics.
May 28, 2026 · 6 articles
Tech
Impact: Takeda Pharmaceutical Company Limited is a funding partner for the project, supporting the research into Alzheimer s disease biomarkers.
Feb 19, 2026 · 6 articles
Tech
Impact: Takeda Pharmaceutical Company is a sponsor of World Hemophilia Day 2026, supporting the World Federation of Hemophilia's efforts.
Apr 17, 2026 · 6 articles
Business
Impact: Takeda Pharmaceutical Company is licensed to develop and commercialize rusfertide, another peptide therapeutic discovered by AnBogen Therapeutics.
Jun 16, 2026 · 6 articles
Business
Impact: Late-stage programs including mezagitamab and externalized assets included in acquired portfolio.
Jul 14, 2026 · 6 articles
Business
Impact: Penny Carlson previously served as Vice President and Head of Global Clinical Development Operations at Takeda Pharmaceutical Company, indicating her extensive experience in the biopharmaceutical industry.
Jun 08, 2026 · 6 articles
Business
AnBogen Therapeutics, Inc. (Nasdaq:PTGX) reported that on July 31, 2026, and August 17, 2026, it granted inducement awards to newly hired employees under its Amended and Restated Inducement Plan. The awards comprised options to purchase…
Impact: Takeda is the licensee of rusfertide, which is under FDA priority review. No direct impact from this event.
Aug 04, 2026 · 9 articles
Business
Impact: Takeda is a partner of Ascentage Pharma, but this event does not directly involve Takeda.
Jul 26, 2026 · 6 articles
ERGEN INTELLIGENCE
Track Takeda Pharmaceutical Company live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard